Health ❯ Healthcare ❯ Oncology

Clinical Trials

Drug Development Immunotherapy Patient Outcomes Pancreatic Cancer Phase 2 Trials Mantle Cell Lymphoma Adverse Effects Metastatic Colorectal Cancer Phase 3 Trials Precision Medicine Treatment Efficacy Emerging Therapies Antibody-Drug Conjugates Patient Response Temozolomide Gastric Cancer Phase II Trials ADRIATIC Trial VERITAC-2 Trial Metastatic Castration-Sensitive Prostate Cancer Phase I Trials DESTINY-Breast05 Trial Small Cell Lung Cancer Abstracts ESMO Congress 2025 Health-Related Quality of Life Adjuvant Treatment Trials EGFR L858R-Mutated NSCLC Breast Cancer Cancer Research IMforte Trial Glioblastoma Targeted Therapies KEYNOTE-B15/EV-304 Trial Melanoma Silevertinib Bladder Cancer Combination Therapies Innovative Therapies Trial Results Diffuse Large B-Cell Lymphoma Phase III Trials HER2-positive Breast Cancer NAPOLI 3 Study Drug Treatments Muscle-Invasive Bladder Cancer Regorafenib Lung Cancer Mitomycin (UGN-102) Pediatric Oncology Gastroenteropancreatic Neuroendocrine Tumors Patient Support Preclinical Models Research Studies Cancer Treatments Treatment Sequencing Therapeutic Efficacy Metastatic Cancer Drug Approval Non-Muscle-Invasive Bladder Cancer Cancer Immunotherapy AI in Healthcare Daraxonrasib Gastroesophageal Adenocarcinoma NRG-LU005 Study RAS/MAPK Pathway Non-Small Cell Lung Cancer

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

The setback reduces near‑term prospects for the targeted antibody‑drug conjugate and shifts the program toward combination and earlier‑line studies.

Erasca Faces Securities Class Actions After April Patent Claim and Patient Death Disclosures

NEJM Paper Shows Zanidatamab Triplet Extends Survival Over Trastuzumab in First‑Line HER2+ Gastroesophageal Cancer

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

NEJM Study and FDA Access Advance Daraxonrasib for Pancreatic Cancer

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

HHS Chief Distances From FDA Replimune Denial as Oncologists Dispute Review

Merck and Other Drugmakers Weigh Bids for Inhibrx’s Keytruda-Linked Cancer Drug

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

Mount Sinai Deploys PRISM AI to Match Cancer Patients to Trials Systemwide

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer